IPL 423323

Drug Profile

IPL 423323

Alternative Names: IPL 400; IPL 4323; Sortac

Latest Information Update: 26 Feb 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class
  • Mechanism of Action Phosphotransferase stimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Transplant rejection

Most Recent Events

  • 26 Feb 2003 No development reported - Preclinical for Psoriasis in Canada (unspecified route)
  • 26 Feb 2003 No development reported - Preclinical for Transplant rejection in Canada (unspecified route)
  • 07 Feb 2000 IPL 423323 is available for licensing (http://www.inflazyme.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top